Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Autologous Stem Cell Transplantation in HIVPositive and HIV-Negative Patients with Lymphoma: A Propensity Score Matched Comparative Analysis

Alessandro Re
* ORCID logo ,
Margherita Oberti
,
Armando Stabile
,
Angelo Andreini
,
Chiara Cattaneo
ORCID logo ,
Chiara Pagani
,
Salvatore Casari
,
Maria Antonia Forleo
,
Cristina Tecchio
ORCID logo ,
Camillo Almici
ORCID logo ,
Alessandra Tucci
ORCID logo ,
Francesco Castelli
ORCID logo ,
Giuseppe Rossi
ORCID logo ,
Mauro Krampera
ORCID logo
Version 1 : Received: 6 August 2024 / Approved: 7 August 2024 / Online: 8 August 2024 (12:14:35 CEST)

How to cite: Re, A.; Oberti, M.; Stabile, A.; Andreini, A.; Cattaneo, C.; Pagani, C.; Casari, S.; Forleo, M. A.; Tecchio, C.; Almici, C.; Tucci, A.; Castelli, F.; Rossi, G.; Krampera, M. Autologous Stem Cell Transplantation in HIVPositive and HIV-Negative Patients with Lymphoma: A Propensity Score Matched Comparative Analysis. Preprints 2024, 2024080537. https://doi.org/10.20944/preprints202408.0537.v1 Re, A.; Oberti, M.; Stabile, A.; Andreini, A.; Cattaneo, C.; Pagani, C.; Casari, S.; Forleo, M. A.; Tecchio, C.; Almici, C.; Tucci, A.; Castelli, F.; Rossi, G.; Krampera, M. Autologous Stem Cell Transplantation in HIVPositive and HIV-Negative Patients with Lymphoma: A Propensity Score Matched Comparative Analysis. Preprints 2024, 2024080537. https://doi.org/10.20944/preprints202408.0537.v1

Abstract

Treatment of HIV-associated lymphoma (HIV-Ly) with autologous stem cell transplantation (ASCT) has shown a surprisingly low relapse rate in several series. The aim of this study was to compare the clinical outcomes of HIV-Ly and lymphomas of the general population receiving ASCT. We compared two series of consecutive HIV-positive and HIV-negative patients, based on a 1:1 propensity score analysis, matching for age, sex, histology, disease status and prior therapies. We identified 44 patients in both groups. All HIV-positive patients received combination antiretroviral therapy (cART). With a median follow-up of 51 months, PFS was significantly higher in HIV-positive patients (4-years PFS 81% and 51%, in HIV-positive and HIV-negative patients, respectively, p=0.027). Four-year OS was 81% for HIV-positive and 67% in HIV-negative patients (p=0.15). The relapse rate was significantly higher in HIV-negative patients (36% vs 23%) (p=0.04). Our results clearly show that ASCT is an effective curative option for HIV-Ly, with better PFS and lower relapse rate compared to uninfected patients. A favourable effect of ASCT on HIV infection and immune system recovery, potential off-target effects of cART or other yet unknown factors may account for this observation.

Keywords

 HIV; Lymphoma; Autologous stem cell transplantation

Subject

Medicine and Pharmacology, Hematology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.